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Abstract
Background: Numerous studies have reported that age-induced increased parathyroid hormone plasma levels
are associated with cognitive decline and dementia. Little is known about the correlation that may exist between
neurological processing speed, cognition and bone density in cases of hyperparathyroidism. Thus, we decided to
determine if parathyroid hormone levels correlate to processing speed and/or bone density.
Methods: The recruited subjects that met the inclusion criteria (n = 92, age-matched, age 18-90 years, mean =
58.85, SD = 15.47) were evaluated for plasma parathyroid hormone levels and these levels were statistically
correlated with event-related P300 potentials. Groups were compared for age, bone density and P300 latency.
One-tailed tests were used to ascertain the statistical significance of the correlations. The study groups were
categorized and analyzed for differences of parathyroid hormone levels: parathyroid hormone levels <30 (n = 30,
mean = 22.7 ± 5.6 SD) and PTH levels >30 (n = 62, mean = 62.4 ± 28.3 SD, p ≤ 02).
Results: Patients with parathyroid hormone levels <30 showed statistically significantly less P300 latency (P300
= 332.7 ± 4.8 SE) relative to those with parathyroid hormone levels >30, which demonstrated greater P300
latency (P300 = 345.7 ± 3.6 SE, p = .02). Participants with parathyroid hormone values <30 (n = 26) were found
to have statistically significantly higher bone density (M = -1.25 ± .31 SE) than those with parathyroid hormone
values >30 (n = 48, M = -1.85 ± .19 SE, p = .04).
Conclusion:  Our findings of a statistically lower bone density and prolonged P300 in patients with high
parathyroid hormone levels may suggest that increased parathyroid hormone levels coupled with prolonged P300
latency may become putative biological markers of both dementia and osteoporosis and warrant intensive
investigation.
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Background
While numerous studies have reported that age-induced
increased parathyroid hormone (PTH) plasma levels are
associated with cognitive decline [1] and dementia [2,3],
little is known about the correlation that may exist
between neurological processing speed and bone density
in cases of hyperparathyroidism or elevated PTH. The
latency of the P300 auditory evoked potential (which
measures processing speed and has been shown to accu-
rately predict memory impairment [4]) has only been
studied with PTH levels in chronic renal failure, and the
last work on this topic, to our knowledge, was published
in 1983 [5].
PTH is anabolic in bone, but when secreted in excess it is
catabolic [6]. Its levels increase with age in both genders,
paralleling the incidence of osteopenia and osteopososis
[7]. Recombinant human PTH 1-34 (teriparatide) is now
being used as a treatment for osteoporosis, and its admin-
istration has been shown to stimulate bone formation
and increase bone mineral density [8]. Interestingly, it has
recently been discovered that intermittent administration
of teriparatide inhibits endogenous PTH production [9],
possibly via negative feedback. So far, there has not yet
been any published research on teriparatide administra-
tion for hyperparathyroidism-induced osteoporosis.
Our greater understanding of PTH has led to lowering of
the reference ranges. In 2003, the American Kidney Foun-
dation recommended that levels should be kept between
35 and 70 pg/ml [10] for stage 3 chronic kidney disease,
which is characterized by a glomerular filtration rate
(GFR) of 30-59 mL/min/1.73 m2, and that an estimated
7.7% of the population suffers [11]. Currently, the accept-
able reference range for parathyroid hormone (PTH) is
between 10 and 60 pg/mL. It has been suggested that,
where there is normal renal function and elevated serum
calcium, an intact PTH concentration of >50 pg/mL
strongly suggests primary hyperparathyroidism [12]. It is
well established that hyperparathyroidism is responsible
for changes in bone metabolism leading to a reduction in
bone mineral density [13], and the National Osteoporosis
Foundation lists hyperparathyroidism as a risk factor for
osteoporosis [14].
The P300 wave is an event related potential that can be
recorded via electroencephalograph (EEG) as a positive
deflection in voltage at a latency of roughly 300 + age mil-
liseconds [4]. The presence, magnitude, topography, and
time of this signal can measure and describe processing
speed. Prolonged P300 latency is an antecedent to mem-
ory loss and cognitive decline [4]. Since hyperparathy-
roidism has already been associated with cognitive
decline [1-3], and increased P300 latency is an early meas-
ure and a better predictor of preclinical dementia than
memory or mental status tests [4], we decided to deter-
mine if PTH levels correlate to processing speed and/or
bone density.
Methods
Participants
The sample consisted of 95 patients from PATH Medical,
an integrative care center and research foundation. Ages
ranged between 18 and 90 years, with a mean of M =
58.85, SD = 15.47. We started with age 18 because many
individuals enter adulthood with poor bone density. Fur-
thermore, osteoporosis is considered to be a childhood
disease, in that childhood and adolescence are the times
when peak bone mass is established [15,16]. Missing data
reduced the sample size for P300 speed of processing
(P300SP) and P300 voltage (P300V) to 92. For Bone Min-
eral Density (BMD), missing data reduced the sample size
to 74. Forty (forty-two percent) were male and fifty-six
(fifty-eight percent) were female. All patients signed an
approved IRB consent form based on an approval from
the PATH Research Foundation IRB committee (registra-
tion # IRB00002334). Patients were made aware that their
results could be used in medical research and by signing
the informed consent, they volunteered to participate in
this study.
In this study, analysis was conducted only on patients
with complete data, (n = 92, age-matched, age 18-90
years, mean = 58.85, SD = 15.47), including measurement
of intact serum PTH levels (BioReference Laboratories)
between 9 AM and 3 PM, BMD, and neurological process-
ing speed as determined by P300 latency. The P300 wave
is an event-related potential that can be recorded via elec-
troencephalograph (EEG) as a positive deflection in volt-
age at a latency of roughly 300 msec. We have found in
previous research that the P300 wave is an accurate predic-
tor of cognitive decline [4], and the "reference" range for
P300 latency is roughly 300 + age msec. In this study,
groups were categorized by patients with: PTH levels <30
(n = 30, mean = 22.7 ± 5.6 SD) and PTH levels >30 (n =
62, mean = 62.4 ± 28.3 SD, p ≤ .02). We used a Hologic
Dual-Energy X-Ray Absorptiometry (DEXA) machine to
measure BMD, focusing on the lumbar vertebrae and the
left hip for all participants. Groups were compared for age,
BMD and P300 latency.
Statistical Analysis
One-tailed tests were used to ascertain the statistical sig-
nificance of the correlations. The statistical analysis of the
data was conducted in four phases. First, the PTH measure
was dichotomized, with PTH values below 30 categorized
as 1 (low), and PTH values above 30 categorized as 2
(high). We used 30 as the cutoff since it is close to but
slightly lower than the midpoint of the current reference
range (35) [12], and since 30 is clearly well below the cur-BMC Endocrine Disorders 2009, 9:21 http://www.biomedcentral.com/1472-6823/9/21
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rent risk range which is not yet well defined. This step was
taken to test the statistical significance of differences in
P300SP, P300V and BMD between low and high levels of
PTH. In addition, the BMD measure was dichotomized
using a median (Md) split procedure (Md = -1.88), with
BMD values equal to or lower than Md categorized as 1
(low), and values greater than Md categorized as 2 (high).
This step was taken to test the statistical significance of dif-
ferences in P300SP and P300V, between low and high lev-
els of BMD.
The second phase of the analysis of the data involved the
calculation of the q-test of normality for P300SP, P300V,
BMD and age. This test was conducted to determine
whether parametric or non-parametric tests of signifi-
cance should be used to examine differences between the
high and low levels of PTH on P300SP, P300V and BMD-
-and between the high and low levels of BMD on P300SP
and P300V. A test of normality was also conducted for
PTH.
The q-test is calculated by dividing the sample's standard
deviation by the sample's range. The obtained q statistic is
compared against a given range for the sample size at
hand, and a q value falling within this range, derived on
the basis of a .025 significance level [17] is interpreted as
indicative that the sample distribution does not depart
statistically significantly from normality. A table due to
Sachs (1984) [18] provides critical ranges of values for
varying sample sizes. For the present sample size of 95 for
age, the q span, ranged between 4.17 and 6.07; for the
P300SP and P300V sample size of 92, it ranged between
4.15 and 6.05; and for BMD's sample size of 74, it ranged
between 4 and 5.87.
The third phase of the analysis of the data involved the
calculation of the correlations among age, BMD, PTH,
P300SP, and P300V.
The fourth phase of the analysis of the data involved the
calculation of tests of statistical significance using the
dichotomized PTH measure as the independent variable
and P300SP, P300V, BMD, and age as dependent varia-
bles. Tests of statistical significance were also calculated
using the dichotomized BMD measure as the independent
variable and P300SP and P300V as the dependent varia-
bles. The effect sizes (ES) of the categorized PTH and BMD
measures were calculated to ascertain the strength of asso-
ciation between the categorized independent and the
dependent variables. Effect size is calculated as
An ES equal to or higher than .20 is considered empiri-
cally consequential.
Results
The following paragraphs describe the outcomes of the
tests of normality, the correlational analyses, and the anal-
yses of differences between the levels of the dichotomized
forms of PTH and BMD.
Tests of Normality
Figure 1 displays the distributions of P300SP, figure 2 dis-
plays the distributions of P300V, figure 3 displays the dis-
tributions of BMD, and figure 4 displays the distributions
of age. For P300SP, P300V, BMD and age, the distribu-
tions tended to approach symmetry, suggesting further,
more formal testing for normality by means of the q-test.
Table 1 displays the q-test outcomes. As shown in this
table, the q value of P300SP was 6.02, that for P300V was
5.23, and that for age was 5.04--all falling within the nor-
mality range for n = 92 of 4.15 to 6.05. For BMD, it was
5.54, falling within the normality range for n = 74 of 4 to
5.87. The q value for PTH was 6.38, falling outside the
4.17 to 6.07 normality range for n = 95. These outcomes
supported the assumption of normality required for the
use of parametric tests in the case of P300SP, P300V,
BMD, and age, and hence, the Pearson correlation coeffi-
cient was used to calculate the level of relation among the
variables in continuous form, and the t-test was used to
ascertain the statistical significance of the differences
between the two categories of PTH on P300SP, P300V,
BMD. Since the hypotheses were stated unidirectionally,
one-tailed tests were used; alpha (a) was set at the .05
level.
Pearson Correlation Coefficients
Table 2 displays the Pearson correlation coefficients. In
this table, BMD and PTH appear in both continuous and
dichotomized form. As evidenced by the outcomes shown
in this table, age proved to be statistically significantly cor-
related with PTH, P300SP, and P300V; BMD proved to be
statistically significantly correlated with PTH in dichot-
omized form; BMD in dichotomized form proved to be
statistically significantly correlated with P300V; PTH
proved to be statistically significantly correlated with
P300P; and P300SP proved to be statistically significantly
correlated with P300V.
The following tables depict the t-test outcomes. They
show the means, standard deviations and standard errors
of the dependent variables for each category of the inde-
pendent variables, and show the t-statistics, p- values, and
effects sizes.
Table 3 displays the t-test outcomes of P300SP by PTH in
categorized form. As shown in this table, the P300SP
mean of the low category of PTH (M = 332.66, SD = 6.39)
proved to be statistically significantly lower than that of
ES t t df =+ [( /( )] .
/ 22 1 2BMC Endocrine Disorders 2009, 9:21 http://www.biomedcentral.com/1472-6823/9/21
Page 4 of 10
(page number not for citation purposes)
the high PTH category (M = 345.68, SD = 28.08), t = -2.12,
df = 90, p = .02 (1-tail test). The effect size was ES = .22--
an effect which, being greater than .20, proved to have
practical significance according to criteria propounded by
Cohen [19] and Kirk [20].
These findings disclosed that level of PTH is positively
associated with level of P300P, and that the strength of the
association is of practical importance. The implications of
these findings are discussed below.
Table 4 displays the t-test outcomes of P300V by PTH in
categorized form. As shown in this table, the P300V mean
of the low category of PTH (M = 5.27, SD = 3.15) did not
differ statistically significantly from that of the high PTH
category (M = 5.28, SD = 2.39), t = -.028, df = 5.31, p = .49
(1-tail test). The effect size was ES = .03, showing a null
effect of PTH on P300V. These findings disclosed a lack of
association between PTH and P300V levels. The implica-
tions of these findings are also discussed below.
Table 5 displays the t-test outcomes of BMD by PTH in cat-
egorized form. As shown in this table, the mean BMD
score of participants in the low category of PTH (M = -
1.25, SD = 1.57) differed statistically significantly from
that of participants in the high PTH category (M = -1.85,
SD = 1.28), t = 1.77, df = 72, p = .04 (1-tail test). The effect
size was ES = .20, showing a substantive effect of PTH on
BMD in terms of criteria propounded by [19] and [20].
These findings disclosed an empirically important associ-
ation between levels of PTH and levels of BMD. The impli-
cations of these findings are also discussed below.
Table 6 displays the t-test outcomes for P300SP by BMD
in categorized form. As shown in this table, the mean age
of participants in the low category of BMD (M = 344.18,
P300 SP Figure 1
P300 SP.
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SD = 30.40) did not differ statistically significantly from
that of participants in the high PTH category (M = 341.99,
SD = 21.48), t = .35, df = 70, p = .36 (1-tail test). The effect
size was ES = .04--an effect which, being lower than .20,
proved to have insubstantial practical significance accord-
ing to criteria propounded by [19] and [20]. This effect
was the same as the Pearson correlation coefficient of
P300SP with the original categorized BMD scores (r = -
.04, p > .05). The implications of these findings are also
discussed below.
Table 7 displays the t-test outcomes for P300V by BMD in
categorized form. As shown in this table, the mean age of
participants in the low category of BMD (M = 5.80, SD =
2.83) differed statistically significantly from that of partic-
ipants in the high BMD category (M = 4.38, SD = 13.66),
t = 2.46, df = 70, p = .005 (1-tail test). The effect size was
ES = .28--an effect which, being greater than .20, proved
to have practical significance. This effect was the same as
the Pearson correlation coefficient of P300SP with the
original categorized BMD scores (r = .-.28, p = .008). The
implications of these findings are also discussed below.
Finally, table 8 displays the means, standard deviations
and standard errors of the two PTH categories. As shown
in this table, the two categories' means differed substan-
tially: category 1 (low): M = 22.65; category 2 (high): 62.37.
Discussion
Our findings suggest that age dependent prolonged P300
latency, as well as age dependent increased PTH levels,
may interact. This is a timely discovery since there has
been a recent influx of research highlighting the connec-
tions between the brain and the bones, and a new field
has been birthed called neuropsychosteology [21,22].
P300 V Figure 2
P300 V.
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Many studies have confirmed neuropsychiatric disease
increases with osteoporosis (OP) [23-25].
Our measurement of PTH did not take into account fac-
tors that could affect analysis: age, gender, menopausal
status, vitamin D and calcium supplementation, smoking,
alcohol consumption, steroid use, family history of oste-
oporosis, physical activity, drugs to control bone and cal-
cium metabolism, rheumatoid arthritis, other diseases
that cause secondary osteoporosis, levels of sex hormones,
etc. Further studies will be needed to clarify all of these
variables in relation to PTH's effects on the aging brain
and aging skeleton.
Based on our findings, we suggest that control of PTH lev-
els may be important for protecting against age-induced
dementia. PTH's potential involvement with dementia
may be explained in the following way: PTH has been
shown to cross the blood-brain barrier [26]. PTH has been
considered a candidate risk factor for senile dementia
because sustained high levels of PTH in the brain may
cause degeneration of specific brain regions due to Ca(2+)
overloading [27,28].
Moreover, OP is a genetic disease and as such the role of
1,25-dihydroxyvitamin D3-receptor gene polymorphisms,
known OP genetic antecedents [29] may contribute in
some way to the age-linked impairments in both parathy-
roid and neurological processing function. It is to be
noted that PTH tides are of short duration while Vitamin
D or calcitriol tides are of long duration. PTH quickly
mobilizes bone calcium, while calcitriol tends to more
slowly increase the absorption of dietary calcium. In the
case of low or no dietary calcium, calcitriol mobilizes
bone calcium together with PTH. Because of this, mixed
effects occur during Vitamin D deficiency, and pseudo- or
BMD Figure 3
BMD.
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secondary hyperparathyroid conditions occur. Further-
more, overnight fasting with reduced absorption of die-
tary calcium associated with age results in a regulatory set
point inducing an increase of PTH secretion with age[30].
It is apparent that PTH levels should be kept below 60 pg/
ml, and we believe based on our findings that these levels
may be lowered still. Further research should involve
P300 latency testing for a larger number of patients and
stratification by age, and correlating PTH levels and BMD.
This study provides the first potential indirect evidence
that may highlight the importance of processing speed as
an early electrophysiological marker of OP, which war-
rants further investigation.
Age Figure 4
Age.
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Table 1: q-Tests for Normality of Distribution. 
Variables
Statistics P300SP P300V BMD PTH Age
SD 28.07 2.66 1.41 30.01 15.47
Range 169 13.93 7.82 191 78
q 6.02 5.23 5.54 6.37 5.04
The q range for normality for a sample size of 93, as was the case for 
P300SP, P300V, PTH, and Age, is 4.16 to 6.07 with a significance level 
of .025. For a sample size of 74, as was the case for Bone density, the 
q range is 4 to 5.87, also with a significance level of .025.
Table 2: Correlation Matrix.
123 4 5 6 7
1. Age 1
2. BMD .03 1
3. BMD1 .01 .62* 1
4. PTH .22* -.04 -.03 1
5. PTH2 .21* -.21* -.11 .62* 1
6. P300SP .40* -.07 -.04 .18* .22* 1
7. P300V -.18* -.15 -.28* -.06 .00 -.19* 1
1Dichotomized (1 <= -1.88; 1.88; 2 > -t-Test Outcomes-1.88) 
2Dichotomized (1 < 30; 2 > 30)
P < 0.05
1Dichotomized (1 <= -* p < .05BMC Endocrine Disorders 2009, 9:21 http://www.biomedcentral.com/1472-6823/9/21
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Increases in PTH levels with age are major factors respon-
sible for age-related increase in bone resorption, and con-
tribute to kidney stone formation as well [31]. PTH levels
need to be monitored in osteoporotic, memory-impaired
people and lowering the levels may be an important part
of the therapeutic process of teriparatide injections. At the
PATH Medical Clinic, PTH levels were reduced by teri-
paratide injections by an average of 20 points, possibly
due to a negative feedback mechanism. This is further sup-
ported by others [9]. Additional research has shown that
teriparatide therapy may need to be supplemented by GH
or GH-dependent factors in order for the anabolic
response of bone [32,33].
Finally, the findings of this study showing a significant
relationship between higher PTH plasma levels and pro-
longed P300 latency as well as a decrease in BMD suggest
that hyperparathyroidism and elevated PTH due in part to
age may lead to dementia and OP. The connection
between elevated PTH and cognitive decline is becoming
well studied. A recent study published in the Journal of
Clinical Endocrinology and Metabolism presented results
of various cognitive testing in postmenopausal women
with hyperparathyroidism, before and after parathyroid-
ectomy, with pre-surgical cognitive impairments improv-
ing after surgery [33]. Further studies are warranted to
confirm the value of increased PTH levels coupled with
increased P300 latency as putative biological markers of
both dementia and OP.
Conclusion
Patients with PTH levels <30 showed statistically signifi-
cantly lesser P300 latency (P300 = 332.7 ± 4.8 SE) relative
to those with high PTH levels (>30), who demonstrated
greater P300 latency (P300 = 345.7 ± 3.6 SE, p = .02). In
addition, participants with PTH values < 30 (n = 26) were
found to have statistically significantly higher bone den-
sity (M = -1.25 ± .31 SE) than those with PTH values > 30
(n = 48, M = -1.85 ± .19 SE, p = .04)
The relevance of this research is more far reaching than
might be initially suspected. A healthy skeleton is more
important to overall health than for just lowering fracture
risk. Healthy bones are intimately involved as an endo-
crine organ performing many important functions includ-
ing the production of red blood cells, immune cells,
platelets, various growth factors, and cytokines [35]. Bone
cells and immune stem cells have a common origin and a
functional relationship called the "osteo-immune rela-
tionship [35-37]" Healthy bones also exert an endocrine
regulation of sugar homeostasis, fat storage, energy
metabolism, cognition and more [38]. These functional
relationships are the basis for the growing field of oste-
oimmunology [35]. Moreover, chronic immune system
overexertion is known to lead to bone loss, promote mus-
cle wasting [35] and increase fat storage [38-41].
This research supports the notion that a strong relation-
ship exists between bone health, brain health, neurologi-
cal competence, endocrine function, immune health, and
genetics, building potential therapeutic bridges across the
Table 3: t-Test of the Difference in P300SP Between the 
Categories of PTH.
P300SP t-Test
PTH NM S D S ET D f p E S *
1 (< 30) 30 332.66 26.39 4.81
-2.12 90 .02 .22
2 (> 30) 62 345.68 28.08 3.57
Total 92 341.44 28.07 2.93
*Effect size
Table 4: t-Test of the Difference in P300V Between the 
Categories of PTH.
P300V t-Test
PTH N M SD SE T df p ES*
1 (< 30) 30 5.27 3.15 .58 .
028 45.31 .49 .03
2 (> 30) 62 5.28 2.39 .30
Total 92 5.29 2.66 .28
*Effect size
Table 5: t-Test of the Difference in BMD Between the Categories 
of PTH.
BMD t-Test
PTH NM S D S E T D f P E S *
1 (< 30) 26 -1.25 1.57 .31
1.77 72 .04 .20
2 (> 30) 48 -1.85 1.28 .19
Total 74 -1.64 1.41 .163
*Effect size
Table 6: t-Test of the Difference in P300SP Between the 
Categories of BMD.
P300SP
BMD NM S D S E t d f p E S *
1 (<=-1.88) 36 344.18 30.40 5.06
.35 70 .36 .04
2 (>-1.88) 36 341.99 21.48 3.58
Total 92 341.44 28.07 2.93
*Effect sizeBMC Endocrine Disorders 2009, 9:21 http://www.biomedcentral.com/1472-6823/9/21
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realms of neuropsychosteology, osteoimmunology, and
nutrigenomics.
Our findings of a statistically lower bone density and pro-
longed P300 in patients with high PTH levels may suggest
that PTH levels coupled with delayed P300 latency may
become putative biological markers of dementia and oste-
oporosis, and further punctuate the importance of these
relationships in the evaluation of overall mental and
physical wellbeing. These conclusions support the notion
that hyperparathyroidism, dysregulation of bone metabo-
lism, osteopenia, osteoporosis, and its sub-clinical prece-
dents have a more systemic impact on overall health,
implicating the opportunity for expanding the scope of
therapeutic intervention to augment treatment for other
related and potentially serious disorders as well. We await
further confirmation of this preliminary study.
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